HLP003: Helus Pharma Supports Psychedelic Research Executive Order
The White House issued an Executive Order aimed at accelerating development and access for psychedelic-based treatments, outlining potential prioritization...
FDA Fast Tracks bbot’s Promising KRAS Pancreatic Cancer Drug
In early Phase 1 dose escalation, BBOT’s pan-KRAS inhibitor BBO-11818 produced a confirmed partial response in pancreatic ductal adenocarcinoma...
Orion’s ODM-212 Granted Orphan Drug Status for Mesothelioma
Orion Pharma has secured US FDA Orphan Drug Designation for ODM-212 in mesothelioma, adding regulatory leverage to a first-in-class...
Atsena to Advance Pivotal Trial for X-Linked Retinoschisis
An independent data monitoring review of Parts A and B of Atsena Therapeutics’ LIGHTHOUSE study found ATSN-201 safe and...
Ascentage Pharma Presents Promising Cancer Research at AACR
Across four AACR posters, Ascentage reported preclinical synergy signals spanning hematologic and solid tumors: olverembatinib enhanced chemotherapy activity in...
Sutro’s Emerging ADC Pipeline Shows Promising Preclinical Data
In preclinical studies presented at AACR, Sutro’s tissue factor–targeted ADC STRO-004 delivered broad antitumor control across multiple TF-expressing solid...
ALXN1840’s Triumph: Neurologic Hope in Wilson Disease
Clinically meaningful neurologic worsening at Week 48 occurred in 25% of patients on standard of care versus 9% on...
Xenon Presents Azetukalner Phase 3 Seizure Study Results
Azetukalner cut monthly focal-onset seizure frequency by a median 53.2% at 25 mg and 34.5% at 15 mg over...
New Zoldonrasib Clinical Data for KRAS G12D Lung Cancer
In a Phase 1 dose-expansion cohort of previously treated KRAS G12D non-small cell lung cancersmall cell lung cancer, zoldonrasib...
meiragtx Announces Positive 3-Year Xerostomia Trial Data
Three-year follow-up from MeiraGTx’s Phase 1 AQUAx study showed sustained, clinically meaningful improvements in patient-reported xerostomia symptoms and persistent...